EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: A prospective study of women diagnosed with GDM during a period of universal GDM screening

Delia Bogdanet iD, Michelle T Castillo, Helen Doheny, Louise Dervan, Miguel A Luque-Fernandez, Jose Halperin, Paula M O'Shea, Fidelma P Dunne iD

Diabetic Medicine · 2023

DOI: 10.1111/dme.15121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, 2023. Verfasst von Delia Bogdanet und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Nursing and Health Sciences, School of Medicine, National University of Ireland, Galway, Ireland. Hauptthemen laut MEDLINE: Diabetes, Gestational, Glucose Intolerance. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Gestational diabetes (GDM) is associated with the development of postpartum (PP) glucose intolerance. Plasma glycated CD59 (pGCD59) is an emerging biomarker for the detection of hyperglycaemia. The aim of this study was to assess the ability of PP pGCD59 to predict the development of PP GI as defined by the 2 h 75 g OGTT using the ADA criteria, in a cohort of women diagnosed with prior GDM in the index pregnancy using the 2 h 75 g OGTT at 24–28 weeks of gestation according to the World Health Organization (WHO) 2013 criteria.

Methods

Of the 2017 pregnant women recruited prospectively 140 women with gestational diabetes had samples for pGCD59 taken PP at the time of the OGTT. The ability of pGCD59 to predict the results of the PP OGTT was assessed using nonparametric receiver operating characteristic (ROC) curves.

Results

Women with PP glucose intolerance had significantly higher PP pGCD59 levels compared to women with normal glucose tolerance PP (3.8 vs. 2.7 SPU). PP pGCD59 identified women who developed glucose intolerance PP with an AUC of 0.80 (95% CI: 0.70–0.91). A PP pGCD59 cut‐off value of 1.9 SPU generated a sensitivity of 100% (95% CI: 83.9–100), specificity of 16.9% (95% CI: 9.8–26.3), positive predictive value of 22.1% (95% CI: 21.0–22.6), and negative predictive value of 100% (95% CI: 87.4–100). PP fasting plasma glucose generated an AUC of 0.96 (95% CI: 0.89–0.99) for the identification of PP glucose intolerance.

Conclusion

Our study found that PP pGCD9 may be a promising biomarker to identify women not requiring PP glucose intolerance screening using the traditional OGTT. While the diagnostic accuracy of pGCD59 is good, fasting plasma glucose remains a better test for the identification of PP glucose intolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes, GestationalGlucose IntoleranceFemalePregnancyHumansProspective StudiesBlood GlucoseGlucose Tolerance TestRetrospective StudiesPostpartum PeriodBiomarkersCD59 Antigens

Stichwörter der Autor:innen

CD59biomarkergestational diabetespostpartum glucose intolerance

Substanzen

Blood GlucoseBiomarkersCD59 protein, humanCD59 Antigens

Autor:innen und Institutionen

  • College of Medicine, Nursing and Health Sciences, School of Medicine, National University of Ireland, Galway, Ireland.
  • Divisions of Haematology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Clinical Biochemistry, Saolta University Health Care Group (SUHCG), Galway University Hospitals, Galway, Ireland.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.

ORCID-Profile: Delia Bogdanet, Fidelma P Dunne

Förderung

  • NIH HHS
  • NIDDK NIH HHS
  • Wellcome Trust
  • Health Research Board
  • Health Service Executive
  • National Institutes of Health

Zitieren

APA

Bogdanet, D., Castillo, M. T., Doheny, H., Dervan, L., Luque-Fernandez, M. A., Halperin, J., O'Shea, P. M., & Dunne, F. P. (2023). The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: A prospective study of women diagnosed with GDM during a period of universal GDM screening. Diabetic Medicine. https://doi.org/10.1111/dme.15121

Vancouver

Bogdanet D, Castillo MT, Doheny H, Dervan L, Luque-Fernandez MA, Halperin J, et al. The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: A prospective study of women diagnosed with GDM during a period of universal GDM screening. Diabetic Medicine. 2023. doi:10.1111/dme.15121

BibTeX
@article{Bogdanet2023,
  author = {Bogdanet, Delia and Castillo, Michelle T and Doheny, Helen and Dervan, Louise and Luque-Fernandez, Miguel A and Halperin, Jose and O'Shea, Paula M and Dunne, Fidelma P},
  title = {The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: A prospective study of women diagnosed with GDM during a period of universal GDM screening},
  journal = {Diabetic Medicine},
  year = {2023},
  doi = {10.1111/dme.15121}
}
Kostenlos starten →